Immediate Impact
1 from Science/Nature 67 standout
Citing Papers
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
2025 Standout
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study
2025 Standout
Works of G. Léon being referenced
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
2014
Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| G. Léon | 34 | 26 | 72 | 258 | 172 | 17 | 387 | |
| Gabriel Medrano-Ramírez | 20 | 92 | 140 | 157 | 12 | 345 | ||
| Mohamed M. Thabet | 6 | 44 | 166 | 107 | 16 | 433 | ||
| Philip Hamann | 10 | 2 | 28 | 74 | 60 | 16 | 407 | |
| Priscilla F. Kerkman | 5 | 26 | 243 | 210 | 17 | 435 | ||
| Minodora Mazur | 6 | 89 | 267 | 108 | 19 | 354 | ||
| Franklin Mullinax | 7 | 6 | 53 | 52 | 72 | 10 | 391 | |
| Juergen H. Bertram | 2 | 7 | 39 | 36 | 151 | 14 | 353 | |
| Masaki Hiraguri | 5 | 31 | 242 | 100 | 15 | 391 | ||
| Jie Ao | 2 | 12 | 11 | 142 | 119 | 14 | 346 | |
| A.E.R. Thomson | 5 | 2 | 105 | 36 | 103 | 14 | 360 |
All Works
Login with ORCID to disown or claim papers
Loading papers...